QuiaPEG Pharmaceuticals Holding AB
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more
Market Cap & Net Worth: QuiaPEG Pharmaceuticals Holding AB (QUIA)
QuiaPEG Pharmaceuticals Holding AB (ST:QUIA) has a market capitalization of $116.79K (Skr1.31 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #41935 globally and #666 in its home market, demonstrating a -44.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying QuiaPEG Pharmaceuticals Holding AB's stock price Skr0.00 by its total outstanding shares 2620377659 (2.62 Billion).
QuiaPEG Pharmaceuticals Holding AB Market Cap History: 2015 to 2025
QuiaPEG Pharmaceuticals Holding AB's market capitalization history from 2015 to 2025. Data shows change from $69.60 Billion to $116.79K (-71.82% CAGR).
Index Memberships
QuiaPEG Pharmaceuticals Holding AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$4.71 Billion | 0.00% | #240 of 281 |
Weight: QuiaPEG Pharmaceuticals Holding AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
QuiaPEG Pharmaceuticals Holding AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how QuiaPEG Pharmaceuticals Holding AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.33x
QuiaPEG Pharmaceuticals Holding AB's market cap is 5.33 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $69.60 Billion | $14.40 Million | $578.00K | 4833.66x | 120423.34x |
| 2016 | $75.73 Billion | $916.00K | $9.60 Million | 82671.60x | 7892.36x |
| 2017 | $16.66 Billion | $3.93 Million | -$4.47 Million | 4236.17x | N/A |
| 2018 | $37.38 Billion | $3.38 Million | -$12.05 Million | 11067.78x | N/A |
| 2019 | $38.09 Billion | $4.47 Million | -$21.11 Million | 8528.18x | N/A |
| 2020 | $18.12 Billion | $1.86 Million | -$27.71 Million | 9736.76x | N/A |
| 2021 | $6.23 Billion | $216.00K | -$22.43 Million | 28853.67x | N/A |
| 2022 | $1.50 Billion | $5.57 Million | -$24.38 Million | 269.17x | N/A |
| 2023 | $15.44 Million | $4.37 Million | -$16.52 Million | 3.53x | N/A |
| 2024 | $2.45 Million | $460.00K | -$28.93 Million | 5.33x | N/A |
Competitor Companies of QUIA by Market Capitalization
Companies near QuiaPEG Pharmaceuticals Holding AB in the global market cap rankings as of March 19, 2026.
Key companies related to QuiaPEG Pharmaceuticals Holding AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
QuiaPEG Pharmaceuticals Holding AB Historical Marketcap From 2015 to 2025
Between 2015 and today, QuiaPEG Pharmaceuticals Holding AB's market cap moved from $69.60 Billion to $ 116.79K, with a yearly change of -71.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr116.79K | -95.24% |
| 2024 | Skr2.45 Million | -84.11% |
| 2023 | Skr15.44 Million | -98.97% |
| 2022 | Skr1.50 Billion | -75.93% |
| 2021 | Skr6.23 Billion | -65.61% |
| 2020 | Skr18.12 Billion | -52.42% |
| 2019 | Skr38.09 Billion | +1.90% |
| 2018 | Skr37.38 Billion | +124.39% |
| 2017 | Skr16.66 Billion | -78.00% |
| 2016 | Skr75.73 Billion | +8.80% |
| 2015 | Skr69.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of QuiaPEG Pharmaceuticals Holding AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.79K USD |
| MoneyControl | $116.79K USD |
| MarketWatch | $116.79K USD |
| marketcap.company | $116.79K USD |
| Reuters | $116.79K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.